Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

During the Trading Day
304.21 +11.71 / +4.00%
As of 4:14pm ET
Day’s Change
During After-Hours   Switch to standard view »
303.50 -0.71 / -0.23%
 
Volume: 71.8K
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$68.8B

Company Description

Biogen, Inc. is a global biotechnology company, which develops markets and manufactures therapies for people living with neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded on November 12, 2003 and is headquartered in Cambridge, MA.

Contact Information

Biogen, Inc.
225 Binney Street
Cambridge Massachusetts 02142
P:(781) 464-2000
Investor Relations:
(781) 464-2442

Employees

Shareholders

Mutual fund holders57.03%
Other institutional35.26%
Individual stakeholders1.15%

Top Executives

George A. ScangosChief Executive Officer
Paul J. ClancyChief Financial Officer & Executive Vice President
Spyridon Artavanis-TsakonasChief Scientific Officer & Senior Vice President
Adriana KaraboutisExecutive VP-Technology & Business Solutions
Matt GriffithsChief Information Officer & Senior VP